Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib (original) (raw)

References

  1. Antonescu CR, Sommer G, Sarran L, Tschernyavsky SJ, Riedel E, Woodruff JM, Robson M, Maki R, Brennan MF, Ladanyi M, DeMatteo RP, Besmer P (2003) Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 9:3329–3337
    CAS PubMed Google Scholar
  2. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/_neu_-overexpressing breast cancer. J Clin Oncol 14:737–744
    CAS PubMed Google Scholar
  3. Benjamin RS, Rankin C, Fletcher C, Blanke C, Von Mehren M, Maki R, Bramwell V, Baker L, Borden E, Demetri GD (2003) Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: intergroup S0033 early results (abstract 3271). Proc Am Soc Clin Oncol 22:814
    Google Scholar
  4. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411:355–365
    CAS PubMed Google Scholar
  5. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB (1995) Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci U S A 92:2558–2562
    CAS PubMed Google Scholar
  6. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylamonipyrimidine derivative. Cancer Res 56:100–104
    CAS PubMed Google Scholar
  7. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139–145
    CAS PubMed Google Scholar
  8. Bümming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engström K, Stierner U, Wängberg B, Jansson S, Ahlman H, Kindblom L-G, Nilsson B (2003) Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 89:460–464
    Article PubMed Google Scholar
  9. Chen H, Kinoshita K, Ohashi A, Shinomura Y, Matsuzawa Y, Kitamura Y, Hirota S (2003) Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors. Int J Cancer 105:130–135
    Article CAS PubMed Google Scholar
  10. Chen MYM, Bechtold RE, Savage PD (2002) Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). AJR 179:1059–1062
    Google Scholar
  11. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC (2002) KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 160:1567–1572
    CAS PubMed Google Scholar
  12. Debiec-Rychter M, Lasota J, Sarlomo-Rikala M, Kordek R, Miettinen M (2001) Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. Cancer Genet Cytogenet 128:24–30
    Article CAS PubMed Google Scholar
  13. Deininger MWN, Druker BJ (2003) Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 55:401–423
    Article CAS PubMed Google Scholar
  14. DeMatteo RP (2002) The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol 9:831–839
    PubMed Google Scholar
  15. DeMatteo RP, Heinrich MC, El-Rifai WM, Demetri G (2002) Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 33:466–477
    Article CAS PubMed Google Scholar
  16. Demetri GD, von Mehren M, Blanke CD, van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CDM, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480
    Google Scholar
  17. Demetri GD, George S, Heinrich MC, Fletcher JA, Fletcher CDM, Desai J, Cohen DP, Scigalla P, Cherrington JM, van den Abbeele AD (2003) Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate (abstract 3273). Proc Am Soc Clin Oncol 22:814
    Google Scholar
  18. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl-positive cells. Nat Med 2:561–566
    CAS PubMed Google Scholar
  19. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU (1992) Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52:4550–4553
    CAS PubMed Google Scholar
  20. Fletcher CDM, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459–465
    Article PubMed Google Scholar
  21. Fletcher JA, Corless CL, Dimitrijevic S, von Mehren M, Eisenberg B, Joensuu H, Fletcher CDM, Blanke C, Demetri GD, Heinrich MC (2003) Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST) (abstract 3275). Proc Am Soc Clin Oncol 22:815
    Google Scholar
  22. Gari M, Goodeve A, Wilson G, Winship P, Langabeer S, Linch D, Vandenberghe E, Peake I, Reilly J (1999) c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 105:894–900
    Article CAS PubMed Google Scholar
  23. George D (2001) Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol 28[Suppl 17]:27–33
  24. Gibson PC, Cooper K (2002) CD117 (KIT): a diverse protein with selective applications in surgical pathology. Adv Anat Pathol 9:65–69
    Google Scholar
  25. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Ziegler AJ (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood 96:925–932
    CAS PubMed Google Scholar
  26. Heinrich MC, Blanke CD, Druker BJ, Corless CL (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692–1703
    Article CAS PubMed Google Scholar
  27. Heinrich MC, Corless CL, Blanke C, Demetri GD, Joensuu H, von Mehren M, McGreevey LS, Wait CL, Griffith D, Chen C-J, Haley A, Kiese B, Druker B, Roberts P, Eisenberg B, Singer S, Silberman S, Dimitrijevic S, Fletcher CDM, Fletcher JA (2002) KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs) (abstract 6). Proc Am Soc Clin Oncol 21:2a
    Google Scholar
  28. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen C-J, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CDM, Fletcher JA (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708–710
    Article CAS PubMed Google Scholar
  29. Heinrich MC, Corless CL, von Mehren M, Joensuu H, Demetri GD, Blanke CD, Dimitrijevic S, Kiese B, Fletcher CDM, Fletcher JA (2003) PDGFRA and KIT mutations correlate with the clinical responses to imatinib mesylate in patients with advanced gastrointestinal stromal tumors (GIST) (abstract 3274). Proc Am Soc Clin Oncol 22:815
    Google Scholar
  30. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580
    CAS PubMed Google Scholar
  31. Hirota S, Nishida T, Isozaki K, Taniguchi M, Nakamura J, Okazaki T, Kitamura Y (2001) Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 193:505–510
    Article CAS PubMed Google Scholar
  32. Hirota S, Nishida T, Isozaki K, Taniguchi M, Nishikawa K, Ohashi A, Takabayashi A, Obayashi T, Okuno T, Kinoshita K, Chen H, Shinomura Y, Kitamura Y (2002) Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology 122:1493–1499
    Google Scholar
  33. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, Kitamura Y (2003) Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors. Gastroenterology 125:660–667
    Article CAS PubMed Google Scholar
  34. Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NCP, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190–2196
    Article CAS PubMed Google Scholar
  35. Hongyo T, Li T, Syaifudin M, Baskar R, Ikeda H, Kanakura Y, Aozasa K, Nomura T (2000) Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res 60:2345–2347
    CAS PubMed Google Scholar
  36. Hubbard SR, Till JH (2000) Protein tyrosine kinase structure and function. Annu Rev Biochem 69:373–398
    Google Scholar
  37. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman SL, Capdeville R, Dimitrijevic S, Druker B, Demetri GD (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056
    CAS PubMed Google Scholar
  38. Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O’Reilly T, Buchdunger E, Black PM, Stiles CD (2000) Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylamino-pyrimidine class. Cancer Res 60:5143–5150
    CAS PubMed Google Scholar
  39. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM (1998) Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259–1269
    CAS PubMed Google Scholar
  40. Krystal GW, Honsawek S, Litz J, Buchdunger E (2000) The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6:3319–3326
    CAS PubMed Google Scholar
  41. Landuzzi L, De Giovanni C, Nicoletti G, Rossi I, Ricci C, Astolfi A, Scopece I, Scotlandi K, Serra M, Bagnara GP, Nanni P, Lollini PL (2000) The metastatic ability of Ewing’s sarcoma cells is modulated by stem cell factor and by its receptor c-kit. Am J Pathol 157:1–9
    PubMed Google Scholar
  42. Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R, Nassar A, Sobin LH, Miettinen M (2000) Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors: a study of 200 cases. Am J Pathol 157:1091–1095
    Google Scholar
  43. Lucas DR, Al-Abbadi M, Tabaczka P, Hamre MR, Weaver DW, Mott MJ (2003) c-Kit expression in desmoid fibromatosis. Comparative immunohistochmical evaluation of two commercial antibodies. Am J Clin Pathol 119:339–345
    PubMed Google Scholar
  44. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ (2002) The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99:1741–1744
    Article CAS PubMed Google Scholar
  45. Mace J, Biermann JS, Sondak V, McGinn C, Hayes C, Thomas D, Baker L (2002) Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 95:2373–2379
    Article CAS PubMed Google Scholar
  46. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR (2002) Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 100:623–626
    Article CAS PubMed Google Scholar
  47. McArthur GA, Demetri GD, Heinrich M, van Oosterom A, Fletcher J, Corless C, Fletcher C, Dimitrijevic S, Nikolova Z (2003) Molecular and clinical analysis of response to imatinib for locally advanced dermatofibrosarcoma protuberans (abstract 781). Proc Am Soc Clin Oncol 22:195
    Google Scholar
  48. Merchant MS, Woo C-W, Mackall CL, Thiele CJ (2002) Potential use of imatinib in Ewing’s sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst 94:1673–1679
    Article CAS PubMed Google Scholar
  49. Östman A, Heldin C-H (2001) Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res 80:1–38
    PubMed Google Scholar
  50. Reilly JT (2002) Class III receptor tyrosine kinases: role in leukaemogenesis. Br J Haematol 116:744–757
    Article CAS PubMed Google Scholar
  51. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen C-J, Xiao S, Tuveson DA, Demetri GD, Fletcher CDM, Fletcher JA (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118–8121
    CAS PubMed Google Scholar
  52. Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, Bruckner JD (2002) Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20:3586–3591
    Article CAS PubMed Google Scholar
  53. Sakuma Y, Sakurai S, Oguni S, Hironaka M, Saito K (2003) Alterations of the c-kit gene in testicular germ cell tumors. Cancer Sci 94:486–491
    CAS PubMed Google Scholar
  54. Sakurai S, Oguni S, Hironaka M, Fukayama M, Morinaga S, Saito K (2001) Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese. Jpn J Cancer Res 92:494–498
    CAS PubMed Google Scholar
  55. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792
    Google Scholar
  56. Schlesinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211–225
    CAS PubMed Google Scholar
  57. Scotlandi K, Manara MC, Strammiello R, Landuzzi L, Benini S, Perdichizzi S, Serra M, Astolifi A, Nicoletti G, Lollini P-L, Bertoni F, Nanni P, Picci P (2003) c-kit receptor expression in Ewing’s sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol 21:1952–1960
    Article PubMed Google Scholar
  58. Singer S, Rubin BP, Lux ML, Chen C-J, Demetri GD, Fletcher CDM, Fletcher JA (2002) Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 20:3898–3905
    Article CAS PubMed Google Scholar
  59. Sirvent N, Maire G, Pedeutour F (2003) Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 37:1–19
    Article CAS PubMed Google Scholar
  60. Sjöblom T, Shimizu A, O’Brian KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Östman A, Heldin C-H (2001) Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61:5778–5783
    CAS PubMed Google Scholar
  61. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, Matsuda H, Kitamura J (1999) Effect of c-kit mutations on prognosis of gastrointestinal stromal tumors. Cancer Res 59:4297–4300
    CAS PubMed Google Scholar
  62. Tian Q, Frierson HF, Krystal GW, Moskaluk CA (1999) Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 154:1643–1647
    CAS PubMed Google Scholar
  63. Tremont-Lukats IW, Gilbert MR (2003) Advances in molecular therapies in patients with brain tumors. Cancer Control 10:125–137
    PubMed Google Scholar
  64. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CDM, Fletcher JA, Demetri GD (2001) STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20:5054–5058
    Article CAS PubMed Google Scholar
  65. Van den Abbeele AD, Badawi RD (2002) Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 38[Suppl 5]S60–S65
  66. Van Oosterom AT, Judson I, Verwej J, Stroobants S, di Paola ED, Dimitrijevic S, Martens M, Webb A, Sciot R, van Glabbeke M, Siberman S, Nielsen OS (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421–1423
    Article PubMed Google Scholar
  67. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichard P, Blay J-Y, Issels M, van Glabbeke M, Donato Di Paola E, Judson IR (2003) Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG (abstract 3272). Proc Am Soc Clin Oncol 22:814
    Google Scholar
  68. Wardelmann E, Neidt I, Bierhoff E, Speidel N, Manegold C, Fischer H-P, Pfeifer U, Pietsch T (2002) C-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid variant. Mod Pathol 15:125–136
    PubMed Google Scholar
  69. Wardelmann E, Losen I, Hans V, Neidt I, Speidel N, Bierhoff E, Heinicke T, Pietsch T, Büttner R, Merkelbach-Bruse S (2003) Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behaviour of gastrointestinal stromal tumors. Int J Cancer 106:887–895
    Article CAS PubMed Google Scholar
  70. Williams DE, Eisenman J, Baird A, Rauch C, Van Ness K, March CJ, Park LS, Martin U, Mochizuki DY, Boswell HS (1990) Identification of a ligand for the c-KIT proto-oncogene. Cell 63:167–174
    CAS PubMed Google Scholar
  71. Zwick E, Bange J, Ullrich A (2002) Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 8:17–23
    Article CAS PubMed Google Scholar

Download references